In the Journals

Intermediate, long-stemmed humeral components provided secure fit in certain patients

Patients with a large humeral canal or with significant proximal bone loss experienced secure distal fit with use of intermediate or long-stemmed humeral components, according to study results.

Researchers followed-up 35 primary shoulder arthroplasties clinically and radiographically for at least 2 years or until revision surgery. A large humeral canal in 18 shoulders and severe preoperative metaphyseal or diaphyseal bone loss in 17 indicated use of an intermediate or long stem.

The researchers found 21 of 35 shoulders achieved excellent or satisfactory results, and no components met criteria to be considered radiographically at risk for clinical loosening. Results showed intraoperative complications included an unrecognized nondisplaced diaphyseal fracture that later displaced in one shoulder.

Deep infection in one shoulder and fracture nonunion in one shoulder were included as late complications, according to the researchers.

Disclosures: Cofield received royalties from Smith & Nephew and DJO. Sperling received royalties from Biomet.

Patients with a large humeral canal or with significant proximal bone loss experienced secure distal fit with use of intermediate or long-stemmed humeral components, according to study results.

Researchers followed-up 35 primary shoulder arthroplasties clinically and radiographically for at least 2 years or until revision surgery. A large humeral canal in 18 shoulders and severe preoperative metaphyseal or diaphyseal bone loss in 17 indicated use of an intermediate or long stem.

The researchers found 21 of 35 shoulders achieved excellent or satisfactory results, and no components met criteria to be considered radiographically at risk for clinical loosening. Results showed intraoperative complications included an unrecognized nondisplaced diaphyseal fracture that later displaced in one shoulder.

Deep infection in one shoulder and fracture nonunion in one shoulder were included as late complications, according to the researchers.

Disclosures: Cofield received royalties from Smith & Nephew and DJO. Sperling received royalties from Biomet.